Research Paper Volume 15, Issue 20 pp 11369—11388
Comprehensive analysis of integrin αvβ3/α6β1 in prognosis and immune escape of prostate cancer
Figure 2. Integrin αvβ3/α6β1 were closely correlated with poor prognosis of PCa patients. (A) Heatmap of integrin αvβ3/α6β1 expression and clinical characteristics of 496 PCa patients in the TCGA cohort. (B) The immunohistochemistry of integrin αvβ3/α6β1 between normal prostate tissues and different grades of PCa tissues in the Human Protein Atlas (HPA). (C) Kaplan-Meier analysis of the OS of patients with high and low ITGB1 expression in the TCGA cohort. (D, E) Kaplan-Meier analysis of the RFS of patients with high and low ITGAV (D) and ITGB1 (E) expression in the TCGA cohort. (F–I) Kaplan-Meier analysis of the biochemical recurrence of patients with high and low ITGAV, ITGA6, ITGB1, and ITGB3 expression in the TCGA cohort. (J–M) Correlations between ITGAV, ITGA6, ITGB1, ITGB3 and androgen receptor (AR).